Drug industry analysts and other observers couldn't be faulted for asking, "Haven't we heard this before?" after Pfizer Inc. on Oct. 10 said it is considering selling is consumer health business.
Even so, the announcement sparked discussion of the pros and cons. On one hand, the consumer unit –which includes the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?